文献速递免疫规划卫生政策与健康促进传染病防控与疫情报告

针对特定年龄的西尼罗病毒疫苗接种项目的成本效果

Cost effectiveness of a targeted age-based West Nile virus vaccination program.
PubMed 文献 · Vaccine · 2017-04-26

研究用数学模型评估针对10至70岁人群、每10年一个队列的西尼罗病毒疫苗接种与不接种的成本和健康结局。结果提示针对重症高风险人群的年龄别接种比普遍接种更具成本效果,且疾病发病率、疫苗成本和感染者发病比例是主要敏感因素。

要点

  • 60岁队列每避免一例神经侵袭性疾病病例的平均成本为664000美元(终身免疫模型)。
  • 终身免疫模型下60岁队列每避免一例残疾的平均成本为1421000美元。

核心结论

  • 针对重症高风险人群的年龄别西尼罗病毒疫苗接种项目比普遍接种更具成本效果。
  • 西尼罗病毒疾病发病率的年度变化、QALY权重和疫苗成本影响成本效果比。

研究设计与样本

  • 使用数学模型估算接种西尼罗病毒疫苗与不接种相比的成本和健康结局。
  • 纳入7个队列,从10岁至70岁每间隔10年一个队列,每个队列随访至90岁。
  • 使用美国监测数据估算西尼罗病毒神经侵袭性疾病发病率,其他数据来自已发表报告。
  • 假设疫苗效力为终身持续或持续10年且每10年给予加强剂量。

主要发现

  • 在两个模型和所有评估结局中,各队列间的成本效果比存在统计学显著差异(Kruskal-Wallis检验p<0.0001)。
  • 终身免疫模型下60岁队列每避免一例神经侵袭性疾病病例的平均成本为664000美元,每避免一例残疾为1421000美元。
  • 10年免疫模型下60岁队列每避免一例神经侵袭性疾病病例的平均成本为882000美元,每避免一例残疾为1887000美元。
  • 60岁队列的这些成本在统计学上显著低于其他队列(p<0.0001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: West Nile virus (WNV) is the leading cause of domestically-acquired arboviral disease in the United States. Several WNV vaccines are in various stages of development. We estimate the cost-effectiveness of WNV vaccination programs targeting groups at increased risk for severe WNV disease. METHODS: We used a mathematical model to estimate costs and health outcomes of vaccination with WNV vaccine compared to no vaccination among seven cohorts, spaced at 10year intervals from ages 10 to 70years, each followed until 90-years-old. U.S. surveillance data were used to estimate WNV neuroinvasive disease incidence. Data for WNV seroprevalence, acute and long-term care costs of WNV disease patients, quality-adjusted life-years (QALYs), and vaccine characteristics were obtained from published reports. We assumed vaccine efficacy to either last lifelong or for 10years with booster doses given every 10years. RESULTS: There was a statistically significant difference in cost-effectiveness ratios across cohorts in both models and all outcomes assessed (Kruskal-Wallis test p<0.0001). The 60-year-cohort had a mean cost per neuroinvasive disease case prevented of $664,000 and disability averted of $1,421,000 in lifelong model and $882,000 and $1,887,000, respectively in 10-year immunity model; these costs were statistically significantly lower than costs for other cohorts (p<0.0001). Vaccinating 70-year-olds had the lowest cost per death averted in both models at around $4.7 million (95%CI $2-$8 million). Cost per disease case averted was lowest among 40- and 50-year-old cohorts and cost per QALY saved lowest among 60-year cohorts in lifelong immunity model. The models were most sensitive to disease incidence, vaccine cost, and proportion of persons developing disease among infected. CONCLUSIONS: Age-based WNV vaccination program targeting those at higher risk for severe disease is more cost-effective than universal vaccination. Annual variation in WNV disease incidence, QALY weights, and vaccine costs impact the cost effectiveness ratios.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Shankar MB, Staples JE, Meltzer MI, et al. Cost effectiveness of a targeted age-based West Nile virus vaccination program. Vaccine. 2017. PMID: 28456529. doi:10.1016/j.vaccine.2016.11.078

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。